Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis (PRNewswire-Asia) - Jul 22, 2024 - "Everest Medicines...announced that the first Chinese patient has been dosed with zetomipzomib in the global Phase 2b PALIZADE trial for the treatment of active lupus nephritis (LN)....PALIZADE is a global, placebo-controlled, randomized, double-blind Phase 2b clinical trial evaluating the efficacy and safety of two dose levels of zetomipzomib in patients with active LN. Target enrollment will be 279 patients, randomly assigned to receive 30 mg of zetomipzomib, 60 mg of zetomipzomib or placebo subcutaneously once weekly for 52 weeks, in addition to standard background therapy."
Trial status • Lupus Nephritis
|